Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Core Insights - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing targeted protein degradation therapies to treat debilitating and life-threatening diseases [3] Company Overview - Arvinas utilizes its PROTAC (PROteolysis TArgeting Chimera) platform to create therapies that leverage the body's natural protein disposal system for the selective degradation of disease-causing proteins [3] - The company is advancing multiple investigational drugs through clinical development, including ARV-102 for neurodegenerative disorders, ARV-393 for relapsed/refractory non-Hodgkin Lymphoma, ARV-806 for KRAS G12D mutated cancers, and vepdegestrant for ER+/HER2- breast cancer [3] Upcoming Events - Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4 at 11:00 a.m. ET in New York [1] - A live audio webcast of the presentation will be available on the company's website [2]